Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking

Mount Sinai Journal of Medicine

Volumn 78, Issue 2, 2011, Pages 221-230

  Wingerchuk, Dean M ^a  

^a MAYO CLINIC   (United States)

Author keywords

cigarette smoking; environment; Epstein Barr virus; infectious mononucleosis; multiple sclerosis; vitamin D

Indexed keywords

CALCITRIOL; VITAMIN D;

ARTICLE; CIGARETTE SMOKING; DISEASE PREDISPOSITION; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; MULTIPLE SCLEROSIS; RISK FACTOR; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

AGE OF ONSET; EARLY DIAGNOSIS; ENVIRONMENT; EPIDEMIOLOGIC STUDIES; EPSTEIN-BARR VIRUS INFECTIONS; GENETIC PREDISPOSITION TO DISEASE; HERPESVIRUS 4, HUMAN; HUMANS; MULTIPLE SCLEROSIS; PRECIPITATING FACTORS; SMOKING; VITAMIN D DEFICIENCY;

EID: 79952996386     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20240     Document Type: Article

References (86)

1. Compston A, Coles A., Multiple sclerosis. Lancet 2008 372 1502-1517.
2. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006 5 932-936. (Pubitemid 44556546)
3. Bush WS, Sawcer SJ, de Jager PL, et al. International Multiple Sclerosis Genetics Consortium (IMSGC). Evidence for polygenic susceptibility to multiple sclerosis-the shape of things to come. Am J Hum Genet 2010 86 621-625.
4. Willer CJ, Dyment DA, Risch NJ, et al. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 2003 100 12877-12882. (Pubitemid 37339993)
5. Ascherio A, Munger KL., Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007 61 288-299. (Pubitemid 46676728)
6. Ascherio A, Munger KL., Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol 2007 61 504-513. (Pubitemid 47068132)
7. Ebers GC., Environmental factors and multiple sclerosis. Lancet Neurol 2008 7 268-277. (Pubitemid 351222732)
8. Kurtzke JF., MS epidemiology world wide: one view of current status. Acta Neurol Scand Suppl 1995 161 23-33.
9. Dean G., Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa. BMJ 1967 2 724-730.
10. Kurtzke JF, Dean G, Botha DP., A method for estimating the age at immigration of white immigrants to South Africa, with an example of its importance. S Afr Med J 1970 44 663-669.
11. Kurtzke JF, Beebe GW, Norman JE, Jr. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS. Neurology 1985 35 672-678. (Pubitemid 15067020)
12. Hammond SR, English DR, McLeod JG., The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 2000 123 968-974. (Pubitemid 30224192)
13. Orton SM, Ramagopalan SV, Brocklebank D, et al. Effect of immigration on multiple sclerosis sex ratio in Canada: the Canadian Collaborative Study. J Neurol Neurosurg Psychiatry 2010 81 31-36.
14. Handel AE, Giovannoni G, Ebers GC, et al. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 2010 6 156-166.
15. Ebers GC, Sadovnick AD, Dyment DA, et al. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet 2004 363 1773-1774. (Pubitemid 38698382)
16. Herrera BM, Ramagopalan SV, Lincoln MR, et al. Parent-of-origin effects in MS: observations from avuncular pairs. Neurology 2008 71 799-803.
17. Ramagopalan SV, Yee IM, Dyment DA, et al. Parent-of-origin effect in multiple sclerosis: observations from interracial matings. Neurology 2009 7 602-605.
18. Willer CJ, Dyment DA, Sadovnick AD, et al. Canadian Collaborative Study Group. Timing of birth and risk of multiple sclerosis: population based study. BMJ 2005 330 120.
19. Hernan MA, Olek MJ, Ascherio A., Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999 53 1711-1718. (Pubitemid 29530344)
20. Wallin MT, Page WF, Kurtzke JF., Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol 2004 55 65-71. (Pubitemid 38067362)
21. Kurtzke JF., Epidemiologic evidence for multiple sclerosis as an infection [published correction appears in Clin Microbiol Rev 1994;7:141:]. Clin Microbiol Rev 1993 6 382-427.
22. Leibowitz U, Antonovsky A, Medalie JM, et al. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry 1966 29 60-68.
23. Handel AE, Williamson AJ, Disanto G, et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One 2010 5 e12496.
24. Levin LI, Munger KL, Rubertone MV, et al. Temporal relationship between elevation of Epstein Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005 293 2496-2500. (Pubitemid 40705731)
25. Sundström P, Juto P, Wadell G, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004 62 2277-2282. (Pubitemid 38787787)
26. DeLorenze GN, Munger KL, Lennette ET, et al. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006 63 839-844. (Pubitemid 43882291)
27. Levin LI, Munger KL, O'Reilly EJ, et al. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010 67 824-830.
28. Ascherio A, Bar-Or A., EBV and brain matter(s)? Neurology 2010 74 1092-1095.
29. Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in multiple sclerosis brain. J Exp Med 2007 204 2899-2912. (Pubitemid 350179559)
30. Willis SN, Stadelmann C, Rodig SJ, et al. Epstein-Barr virus is not a characteristic feature of multiple sclerosis brain. Brain 2009 132 3318-3328.
31. Sargsyan SA, Shearer AJ, Ritchie AM, et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010 74 1127-1135.
32. Goldberg P., Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence (a view- point). Part 1: sunlight, dietary factors and epidemiology. Int J Environ Stud 1974 6 19-27.
33. Webb AR, Kline L, Holick MF., Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988 67 373-378.
34. Lemire JM, Archer DC., 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991 87 1103-1107.
35. Cantorna MT, Hayes CE, DeLuca HF., 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996 93 7861-7864. (Pubitemid 26277129)
36. Holick MF., Vitamin D: a millennium perspective. J Cell Biochem 2003 88 296-307.
37. Yetley EA., Assessing the vitamin D status of the US population. Am J Clin Nutr 2008 88 suppl 558S-564S.
38. Matsuoka LY, Ide L, Wortsman J, et al. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab 1987 64 1165-1168. (Pubitemid 17074773)
39. Matsuoka LY, Wortsman J, Haddad JG, et al. In vivo threshold for cutaneous synthesis of vitamin D3. J Lab Clin Med 1989 114 301-305. (Pubitemid 19221264)
40. Holick MF., Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004 80 suppl 1678S-1688S.
41. Lips P., Vitamin D physiology. Prog Biophys Mol Biol 2006 92 4-8. (Pubitemid 43831956)
42. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006 84 18-28. (Pubitemid 44699167)
43. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Published November 30, 2010. Accessed December 23, 2010.
44. Nieves J, Cosman F, Herbert J, et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994 44 1687-1692. (Pubitemid 24286648)
45. Van der Mei IA, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007 254 581-590. (Pubitemid 46781963)
46. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006 296 2832-2838. (Pubitemid 44969183)
47. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004 62 60-65. (Pubitemid 38082871)
48. Kampman MT, Wilsgaard T, Mellgren SI., Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 2007 254 471-477. (Pubitemid 46786722)
49. Van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype and risk of multiple sclerosis: a case-control study. BMJ 2003 327 316-321.
50. Ghadirian P, Jain M, Ducic S, et al. Nutritional factors in the aetiology of multiple sclerosis: a case control study in Montreal, Canada. Int J Epidemiol 1998 27 845-852. (Pubitemid 28504973)
51. Freedman DM, Dosemeci M, Alavanja MC., Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup Environ Med 2000 57 418-421. (Pubitemid 30312755)
52. Islam T, Gauderman WJ, Cozen W, et al. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007 69 381-388. (Pubitemid 47205666)
53. Westberg M, Feychting M, Jonsson F, et al. Occupational exposure to UV light and mortality from multiple sclerosis. Am J Ind Med 2009 52 353-357.
54. Embry AF, Snowdon LR, Vieth R., Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000 48 271-272. (Pubitemid 30617053)
55. Tremlett H, van der Mei IA, Pittas F, et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 2008 31 271-279.
56. Rovaris M, Comi G, Sormani MP, et al. Effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis. Ann Neurol 2001 49 415-416. (Pubitemid 32202800)
57. Killestein J, Rep MH, Meilof JF, et al. Seasonal variation in immune measurements and MRI markers of disease activity in MS. Neurology 2002 58 1077-1080. (Pubitemid 34298549)
58. Smolders J, Menheere P, Kessels A, et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008 14 1220-1224.
59. Simpson S, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010 68 193-203.
60. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010 67 618-624.
61. Holmoy T, Moen SM, Gundersen TA, et al. 25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult Scler 2009 15 1280-1285.
62. Wingerchuk DM, Lesaux J, Rice GP, et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005 76 1294-1296. (Pubitemid 41208389)
63. Wingerchuk DM., Supplementing our understanding of vitamin D and multiple sclerosis. Neurology 2010 74 1846-1847.
64. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010 74 1852-1859.
65. Ascherio A, Munger KL, Simon KC., Vitamin D and multiple sclerosis. Lancet Neurol 2010 9 599-612.
66. Antonovsky A, Leibowitz U, Smith HA, et al. Epidemiologic study of multiple sclerosis in Israel. Arch Neurol 1965 13 183-193.
67. Ghadirian P, Dadgostar B, Azani R, et al. A case-control study of the association between socio-demographic, lifestyle and medical history factors and multiple sclerosis. Can J Public Health 2001 92 281-285. (Pubitemid 33019483)
68. Casetta I, Granieri E, Malagu S, et al. Environmental risk factors and multiple sclerosis: a community-based, case-control study in the province of Ferrara, Italy. Neuroepidemiology 1994 13 120-128. (Pubitemid 24128263)
69. Riise T, Nortvedt MW, Ascherio A., Smoking is a risk factor for multiple sclerosis. Neurology 2003 61 1122-1124. (Pubitemid 37461949)
70. Villard-Mackintosh L, Vessey MP., Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception 1993 47 161-168. (Pubitemid 23062255)
71. Thorogood M, Hannaford PC., The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol 1998 105 1296-1299. (Pubitemid 29002831)
72. Hernan MA, Jick SS, Logroscino G, et al. Cigarette smoking and the progression of multiple sclerosis. Brain 2005 128 1461-1465. (Pubitemid 40826198)
73. Hernan MA, Olek MJ, Ascherio A., Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001 154 69-74. (Pubitemid 32565688)
74. Hedstrom AK, Baarnhielm M, Olsson T, et al. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009 73 696-701.
75. Sundström P, Nyström L, Hallmans G., Smoke exposure increases the risk for multiple sclerosis. Eur J Neurol 2008 15 579-583. (Pubitemid 351677503)
76. Montgomery SM, Bahmanyar S, Hillert J, et al. Maternal smoking during pregnancy and multiple sclerosis amongst offspring. Eur J Neurol 2008 15 1395-1399.
77. Mikaeloff Y, Caridade G, Tardieu M, et al. Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 2007 130 2589-2595. (Pubitemid 47511711)
78. Healy BC, Ali EN, Guttmann CR, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009 66 858-864.
79. Pittas F, Ponsonby AL, van der Mei IA, et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol 2009 256 577-585.
80. Sundström P, Nyström L., Smoking worsens the prognosis in multiple sclerosis. Mult Scler 2008 14 1031-1035.
81. Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009 73 504-510.
82. Handunnetthi L, Ramagopalan SV, Ebers GC., Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology 2010 74 1905-1910.
83. Simon KC, van der Mei IA, Munger KL, et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 2010 74 1365-1371.
84. De Jager PL, Chibnik LB, Cui J, et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009 8 1111-1119.
85. Goodin DS., The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One 2009 4 e4565.
86. Ramagopalan SV, Dobson R, Meier UC, et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010 9 727-739.